Axio BioPharma has announced that they are now accepting recombinant protein manufacturing projects.

Located within Forward BIOLABS at 504 South Rosa Rd., Suite 200, Madison, WI, Axio BioPharma is poised to meet the growing demands of the biopharmaceutical industry.

"Our mission at Axio BioPharma is to be the preferred partner for companies advancing cutting-edge biologics. With our innovative manufacturing approach, we are committed to accelerating the development of life-saving therapies," said Justin Byers, Founder and CEO of Axio BioPharma.

Axio BioPharma specializes in research-grade manufacturing of monoclonal antibodies (mAbs), focusing on small-scale production ranging from 50?mL to 2?L. The company's team of industry-leading experts is equipped to tackle unique program challenges, ensuring efficient and reliable results.

In addition, Axio BioPharma supports mammalian-expressed proteins with scalable production capabilities. This flexibility allows the company to meet the needs of research and development programs, providing customized solutions that advance clients' biologics pipelines.

Looking ahead, Axio BioPharma is committed to expanding its capabilities to better serve the biopharmaceutical community. GMP mammalian manufacturing capabilities are planned to be launched in early 2028. This strategic expansion will enable Axio BioPharma to support clients from early research stages through clinical manufacturing, further accelerating the development of life-saving therapies.

"By combining our expertise with flexible production scales, we are able to support our clients throughout various stages of their research and development. We understand the challenges in bringing new therapies to market, and we're here to make that process faster and more efficient. Our upcoming GMP services will allow us to provide even more comprehensive support to our clients," added Byers.